Kuala Lumpur: Prostate cancer stands as the third most common cancer among Malaysian men, with 70 percent of cases diagnosed at advanced stages. This delayed detection significantly reduces the chances of successful treatment and survival.
According to BERNAMA News Agency, the urgency for enhanced early detection methods and cost-effective treatment options is paramount to improve outcomes for Malaysian prostate cancer patients. Malaysia is emerging as a leader in adopting advanced prostate cancer treatments and diagnostics, such as Prostate-Specific Membrane Antigen (PSMA) PET scans and Stereotactic Body Radiotherapy (SBRT), within its hospitals.
PSMA PET scans enable precise detection of prostate cancer even in its earliest stages, improving diagnostic accuracy and allowing timely interventions. SBRT delivers high doses of radiation with precision, reducing the impact on healthy tissues and shortening treatment durations. Unlike conventional imaging methods, these modern technologies offer quicker diagnoses and more efficient treatments.
Dr Lingeswaran Kasilingam, a consultant nuclear medicine physician at Beacon Hospital, highlights that PSMA PET scans target the PSMA receptor, allowing for high-resolution imaging capable of detecting even the smallest cancerous lesions. This method offers greater sensitivity, efficiency, and accuracy compared to traditional methods like bone scans.
PSMA PET scans also play a role in monitoring prostate cancer post-treatment. They can identify even the smallest areas of recurrence, ensuring timely interventions to control the disease and improve outcomes. The reduced radiotracer dose minimizes radiation exposure, making it a safer option for follow-up scans.
SBRT, described as a transformative development, delivers targeted radiation with sub-millimetre precision, minimizing damage to surrounding tissues. It reduces side effects and treatment time, improving patient outcomes and quality of life. Dr Mohamed Ibrahim A Wahid, consultant clinical oncologist at Beacon Hospital, states that SBRT’s success rate is remarkable, with a five-year control rate of 95 to 97 percent.
Radioligand Therapy (RLT) is another promising treatment for advanced prostate cancer, targeting PSMA receptors on cancer cells. Clinical trials have been underway since 2017 to assess RLT’s effectiveness.
Dr Lingeswaran stresses the importance of early detection for improving prostate cancer outcomes. Men aged 50 and above should prioritize regular screenings, especially those with a family history of the disease. Early detection through PSA tests, digital rectal exams, and PSMA PET scans is crucial for survival rates and quality of life.
Malaysia’s availability of advanced cancer treatments like SBRT and PSMA PET scans has positioned it as a leading destination for medical tourism. Dr Mohamed Ibrahim notes that Malaysia offers world-class care at a fraction of the cost compared to neighboring countries, attracting international patients seeking specialized cancer treatments.
Malaysia’s early adoption of advanced therapies has established it as a regional leader in cancer care, drawing patients from Australia, Iran, Indonesia, and beyond. The future of prostate cancer treatment in Malaysia looks promising, focusing on precision medicine, cost-effective treatments, and improved patient outcomes. By embracing innovative diagnostic and treatment technologies, Malaysia enhances survival rates and quality of life for its citizens while establishing itself as a global leader in medical tourism for cancer care.